FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313574894> ?p ?o ?g. }

• W4313574894 endingPage "2807" @default.
• W4313574894 startingPage "2793" @default.
• W4313574894 abstract "Radiolabeled heterobivalent peptidic ligands (HBPLs) are a highly promising compound class for the sensitive and specific visualization of tumors as they often exhibit superior properties compared to their monospecific counterparts and are able to concomitantly or complementarily address different receptor types. The combination of two receptor-specific agents targeting the epidermal growth factor receptor (EGFR) and the integrin αvβ3 in one HBPL would constitute a synergistic combination of binding motifs as these two receptor types are concurrently overexpressed on several human tumor types and are closely associated with disease progression and metastasis. Here, we designed and synthesized two heterobivalent radioligands consisting of the EGFR-specific peptide GE11 and αvβ3-specific cyclic RGD peptides, bearing a (1,4,7-triazacyclononane-4,7-diyl)diacetic acid-1-glutaric acid chelator for efficient radiolabeling and linkers of different lengths between both peptides. Both HBPLs were radiolabeled with 68Ga3+ in high radiochemical yields, purities of 96-99%, and molar activities of 36-88 GBq/μmol. [68Ga]Ga-1 and [68Ga]Ga-2 were evaluated for their log D(7.4) and stability toward degradation by human serum peptidases, showing a high hydrophilicity for both agents of -3.07 ± 0.01 and -3.44 ± 0.08 as well as a high stability toward peptidase degradation in human serum with half-lives of 272 and 237 min, respectively. Further on, the in vitro receptor binding profiles of both HBPLs to the target EGF and integrin αvβ3 receptors were assessed on EGFR-positive A431 and αvβ3-positive U87MG cells. Finally, we investigated the in vivo pharmacokinetics of HBPL [68Ga]Ga-1 by positron emission tomography/computed tomography imaging in A431 tumor-bearing xenograft mice to assess its potential for the receptor-specific visualization of EGFR- and/or αvβ3-expressing tumors. In these experiments, [68Ga]Ga-1 demonstrated a tumor uptake of 2.79 ± 1.66% ID/g, being higher than in all other organs and tissues apart from kidneys and blood at 2 h p.i. Receptor blocking studies revealed the observed tumor uptake to be solely mediated by integrin αvβ3, whereas no contribution of the GE11 peptide sequence to tumor uptake via the EGFR could be determined. Thus, the approach to develop radiolabeled EGFR- and integrin αvβ3-bispecific HBPLs is in general feasible although another peptide lead structure than GE11 should be used as the basis for the EGFR-specific part of the agents." @default.
• W4313574894 created "2023-01-06" @default.
• W4313574894 creator A5001612018 @default.
• W4313574894 creator A5024106348 @default.
• W4313574894 creator A5038914134 @default.
• W4313574894 creator A5044741435 @default.
• W4313574894 creator A5052647484 @default.
• W4313574894 creator A5075626840 @default.
• W4313574894 creator A5081680068 @default.
• W4313574894 date "2023-01-04" @default.
• W4313574894 modified "2023-10-04" @default.
• W4313574894 title "Synthesis, Radiolabeling, and <i>In Vitro</i> and <i>In Vivo</i> Characterization of Heterobivalent Peptidic Agents for Bispecific EGFR and Integrin α_vβ₃ Targeting" @default.
• W4313574894 cites W1124790770 @default.
• W4313574894 cites W1518071796 @default.
• W4313574894 cites W1644406610 @default.
• W4313574894 cites W1965617754 @default.
• W4313574894 cites W1979354807 @default.
• W4313574894 cites W1987370132 @default.
• W4313574894 cites W1988142400 @default.
• W4313574894 cites W2004872298 @default.
• W4313574894 cites W2010559811 @default.
• W4313574894 cites W2013840138 @default.
• W4313574894 cites W2016535122 @default.
• W4313574894 cites W2020804208 @default.
• W4313574894 cites W2027743915 @default.
• W4313574894 cites W2029773366 @default.
• W4313574894 cites W2041993682 @default.
• W4313574894 cites W2056846662 @default.
• W4313574894 cites W2061891460 @default.
• W4313574894 cites W2078278161 @default.
• W4313574894 cites W2087360616 @default.
• W4313574894 cites W2088361522 @default.
• W4313574894 cites W2101051932 @default.
• W4313574894 cites W2102621613 @default.
• W4313574894 cites W2107698466 @default.
• W4313574894 cites W2116731538 @default.
• W4313574894 cites W2140106196 @default.
• W4313574894 cites W2140859605 @default.
• W4313574894 cites W2147000598 @default.
• W4313574894 cites W2153771484 @default.
• W4313574894 cites W2158256377 @default.
• W4313574894 cites W2172001068 @default.
• W4313574894 cites W2331853981 @default.
• W4313574894 cites W2418420084 @default.
• W4313574894 cites W2476760949 @default.
• W4313574894 cites W2516044053 @default.
• W4313574894 cites W2578530566 @default.
• W4313574894 cites W2611637729 @default.
• W4313574894 cites W2752781362 @default.
• W4313574894 cites W2767336741 @default.
• W4313574894 cites W2770246261 @default.
• W4313574894 cites W2784294392 @default.
• W4313574894 cites W2792323164 @default.
• W4313574894 cites W2794043418 @default.
• W4313574894 cites W2883522606 @default.
• W4313574894 cites W2902070849 @default.
• W4313574894 cites W2947606808 @default.
• W4313574894 cites W2964808638 @default.
• W4313574894 cites W2965769363 @default.
• W4313574894 cites W3032683500 @default.
• W4313574894 cites W3041814420 @default.
• W4313574894 cites W3045789922 @default.
• W4313574894 cites W3072907515 @default.
• W4313574894 cites W3129961448 @default.
• W4313574894 cites W3130203365 @default.
• W4313574894 cites W3149450251 @default.
• W4313574894 cites W3168529792 @default.
• W4313574894 cites W4244550254 @default.
• W4313574894 doi "https://doi.org/10.1021/acsomega.2c07484" @default.
• W4313574894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36687076" @default.
• W4313574894 hasPublicationYear "2023" @default.
• W4313574894 type Work @default.
• W4313574894 citedByCount "1" @default.
• W4313574894 countsByYear W43135748942023 @default.
• W4313574894 crossrefType "journal-article" @default.
• W4313574894 hasAuthorship W4313574894A5001612018 @default.
• W4313574894 hasAuthorship W4313574894A5024106348 @default.
• W4313574894 hasAuthorship W4313574894A5038914134 @default.
• W4313574894 hasAuthorship W4313574894A5044741435 @default.
• W4313574894 hasAuthorship W4313574894A5052647484 @default.
• W4313574894 hasAuthorship W4313574894A5075626840 @default.
• W4313574894 hasAuthorship W4313574894A5081680068 @default.
• W4313574894 hasBestOaLocation W43135748941 @default.
• W4313574894 hasConcept C12554922 @default.
• W4313574894 hasConcept C13935069 @default.
• W4313574894 hasConcept C150903083 @default.
• W4313574894 hasConcept C170493617 @default.
• W4313574894 hasConcept C185592680 @default.
• W4313574894 hasConcept C195687474 @default.
• W4313574894 hasConcept C202751555 @default.
• W4313574894 hasConcept C207001950 @default.
• W4313574894 hasConcept C2779281246 @default.
• W4313574894 hasConcept C2779438470 @default.
• W4313574894 hasConcept C502942594 @default.
• W4313574894 hasConcept C55493867 @default.
• W4313574894 hasConcept C71240020 @default.
• W4313574894 hasConcept C86803240 @default.
• W4313574894 hasConceptScore W4313574894C12554922 @default.

• next